Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs).

There are several future obstacles that still need to be overcome for RiboTaC technology to fully realize its potential. Despite these challenges, the authors are optimistic about its prospects, which have the potential to fundamentally transform the treatment of a wide range of diseases.